Skip to main content

LIFE

Stock
Health Care
Biotechnology

Performance overview

LIFE Price
Price Chart

Forward-looking statistics

Beta
1.21
Risk
78.97%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Company info

SectorHealth Care
IndustryBiotechnology
Employees69
Market cap$119.4M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth-0.6
Credit+3.7
Liquidity+0.2
Inflation-0.7
Commodities-1.5
Interest Rates-2.1

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio-2.53
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayAugust 10, 2023
Next dividend day—
Ex. dividend day—

News

5 Top Stocks to Play Earnings Beat Potential

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap American Woodmark (AMWD), Skechers (SKX), Workday (WDAY), aTyr Pharma (LIFE) and Modine Manufacturing (MOD).

Zacks Investment Research (September 4, 2023)
What US Stocks Are The Largest Gainers In 2021?

The last two weeks haven't exactly been ideal for the major US indices. Since the end of August, the Dow Jones Industrial Average, the S&P 500, and the Nasdaq 100 have been down 1.54%, 0.93%, and 0.51%, respectively.

Benzinga (September 17, 2021)
A small pharmaceutical company has surged 137% in 2 days after positive results in trials for lung disease treatment

aTyr says it plans to meet with the FDA to present its data on ATYR1923, a potential treatment for pulmonary sarcoidosis.

Business Insider (September 14, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free